(CABA) Cabaletta Bio - Ratings and Ratios

Cabaletta Bio, Inc. (NASDAQ:CABA) is a clinical-stage biotechnology company specializing in the development of innovative T cell therapies designed to treat B cell-mediated autoimmune diseases. The companys lead product candidate, CABA-201, is a fully human anti-CD19 binder currently undergoing Phase 1/2 clinical trials for conditions such as dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. Additionally, Cabaletta is advancing DSG3-CAART and MuSK-CAART, both in Phase I/II trials for mucosal pemphigus vulgaris and anti-MuSK antibody-positive myasthenia gravis, respectively.

Cabaletta has established strategic collaborations with prominent institutions and companies, including the University of Pennsylvania, Childrens Hospital of Philadelphia, Nanjing IASO Biotherapeutics Co., Ltd, Oxford Biomedica, and WuXi Advanced Therapies, Inc. These partnerships enhance its research and development capabilities, supporting its mission to deliver cutting-edge therapies. The company, originally known as Tycho Therapeutics, Inc., rebranded as Cabaletta Bio, Inc. in August 2018 and is headquartered in Philadelphia, Pennsylvania, with operations commencing in 2017.

From a technical standpoint, CABAs stock shows a bearish trend, trading below its 20-day, 50-day, and 200-day moving averages (SMA 20: 2.22, SMA 50: 2.32, SMA 200: 5.05). The average trading volume over 20 days is approximately 1,395,804 shares, with a last price of $1.76 and an Average True Range (ATR) of 0.23, indicating moderate volatility. Fundamentally, Cabaletta has a market capitalization of $96.78 million, a price-to-book (P/B) ratio of 0.55, and a return on equity (RoE) of -59.78, reflecting significant R&D investments and operating losses typical of early-stage biotech companies.

3-Month Forecast: CABA is expected to maintain its bearish momentum, with potential price fluctuations within a range of $1.50 to $2.50, influenced by trial updates and broader market sentiment. Positive clinical data could trigger a rally, while negative results may deepen the decline. The stocks moderate volatility, as indicated by the ATR, suggests traders should anticipate swings of up to 10-15% in either direction. Strategic collaborations and regulatory developments will remain key drivers of short-term price action.